Last reviewed · How we verify
DTaP//PRP-T Combined Vaccine
DTaP//PRP-T Combined Vaccine is a Vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infection in infants and children. Also known as: ACTACEL.
This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b (Hib) by presenting inactivated toxoids and conjugated polysaccharide antigens.
This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b (Hib) by presenting inactivated toxoids and conjugated polysaccharide antigens. Used for Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infection in infants and children.
At a glance
| Generic name | DTaP//PRP-T Combined Vaccine |
|---|---|
| Also known as | ACTACEL |
| Sponsor | Sanofi |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
DTaP//PRP-T is a pentavalent vaccine combining diphtheria and tetanus toxoids, acellular pertussis antigens, and Hib polysaccharide conjugated to tetanus protein. The vaccine triggers both humoral (antibody) and cell-mediated immune responses, providing protection against these five bacterial pathogens. The conjugate technology enhances immunogenicity of the Hib component, particularly in young infants.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infection in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants (PHASE3)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
- DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (PHASE3)
- Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth (PHASE3)
- Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP//PRP-T Combined Vaccine CI brief — competitive landscape report
- DTaP//PRP-T Combined Vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about DTaP//PRP-T Combined Vaccine
What is DTaP//PRP-T Combined Vaccine?
How does DTaP//PRP-T Combined Vaccine work?
What is DTaP//PRP-T Combined Vaccine used for?
Who makes DTaP//PRP-T Combined Vaccine?
Is DTaP//PRP-T Combined Vaccine also known as anything else?
What drug class is DTaP//PRP-T Combined Vaccine in?
What development phase is DTaP//PRP-T Combined Vaccine in?
What are the side effects of DTaP//PRP-T Combined Vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infection in infants and children
- Also known as: ACTACEL
- Compare: DTaP//PRP-T Combined Vaccine vs similar drugs
- Pricing: DTaP//PRP-T Combined Vaccine cost, discount & access